{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:08:20Z","timestamp":1789564100805,"version":"build-2803163510"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012304","name":"Johns Hopkins University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jconrel.2021.05.035","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T23:33:26Z","timestamp":1622244806000},"page":"527-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration"],"prefix":"10.1016","volume":"335","author":[{"given":"Siva P.","family":"Kambhampati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A.","family":"Bhutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A.","family":"Lutty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangaramanujam M.","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jconrel.2021.05.035_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007945","article-title":"Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD","volume":"4","author":"Ma","year":"2009","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jconrel.2021.05.035_bb0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaophthalmol.2016.3519","article-title":"Histopathological insights into choroidal vascular loss in clinically documented cases of age-related macular degeneration","volume":"134","author":"Seddon","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.jconrel.2021.05.035_bb0015","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8125267","article-title":"Choriocapillaris loss in advanced age-related macular degeneration","volume":"2018","author":"Moreira-Neto","year":"2018","journal-title":"J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.mam.2012.06.003","article-title":"Animal models of age related macular degeneration","volume":"33","author":"Pennesi","year":"2012","journal-title":"Mol. Asp. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0025","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2021.05.035_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000337154","article-title":"Neovascular age-related macular degeneration","volume":"227","author":"Veritti","year":"2012","journal-title":"Ophthalmologica"},{"issue":"14","key":"10.1016\/j.jconrel.2021.05.035_bb0035","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1167\/iovs.16-20049","article-title":"Distribution and quantification of choroidal macrophages in human eyes with age-related macular degeneration","volume":"57","author":"McLeod","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2021.05.035_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004389","article-title":"\u201cSmall blood vessels: big health problems?\u201d: scientific recommendations of the national institutes of health workshop","volume":"5","author":"Bosetti","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.jconrel.2021.05.035_bb0045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrd3745","article-title":"Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.survophthal.2005.12.001","article-title":"The role of inflammation in the pathogenesis of age-related macular degeneration","volume":"51","author":"Donoso","year":"2006","journal-title":"Surv. Ophthalmol."},{"issue":"10","key":"10.1016\/j.jconrel.2021.05.035_bb0055","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1523\/JNEUROSCI.3153-13.2014","article-title":"Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina","volume":"34","author":"Wang","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2021.05.035_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preteyeres.2014.11.004","article-title":"Retinal microglia: just bystander or target for therapy?","volume":"45","author":"Karlstetter","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","article-title":"Understanding age-related macular degeneration (AMD): relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex","volume":"33","author":"Bhutto","year":"2012","journal-title":"Mol. Asp. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2021.05.035_bb0070","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1167\/iovs.03-0097","article-title":"Macrophage depletion inhibits experimental choroidal neovascularization","volume":"44","author":"Sakurai","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2021.05.035_bb0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/1440-1681.12099","article-title":"Brain and retinal microglia in health and disease: an unrecognized target of the renin\u2013angiotensin system","volume":"40","author":"McCarthy","year":"2013","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/eye.2008.206","article-title":"Macrophages in neovascular age-related macular degeneration: friends or foes?","volume":"23","author":"Skeie","year":"2009","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0085","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model","volume":"57","author":"Park","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0090","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"7","key":"10.1016\/j.jconrel.2021.05.035_bb0095","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/IAE.0000000000000081","article-title":"Exacerbation of Choroidal and retinal pigment epithelial atrophy after anti\u2013vascular endothelial growth factor treatment in Neovascular age-related macular degeneration","volume":"34","author":"Young","year":"2014","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/IAE.0000000000000374","article-title":"Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"35","author":"Xu","year":"2015","journal-title":"Retina"},{"issue":"9900","key":"10.1016\/j.jconrel.2021.05.035_bb0105","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","article-title":"Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes","volume":"98","author":"Julien","year":"2014","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0264619613481778","article-title":"Living with age-related macular degeneration treatment: patient experiences of being treated with ranibizumab (Lucentis)(R) intravitreal injections","volume":"31","author":"Thetford","year":"2013","journal-title":"Br. J. Vis. Impair."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/jop.2012.0173","article-title":"Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors","volume":"29","author":"Veritti","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2021.05.035_bb0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OPTH.S133332","article-title":"Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning","volume":"11","author":"Miyamoto","year":"2017","journal-title":"Clin. Ophthalmol. (Auckland, NZ)"},{"key":"10.1016\/j.jconrel.2021.05.035_bb0130","first-page":"37","article-title":"When Anti-VEGF fails in AMD patients: 3 treatment approaches","author":"Weiner","year":"2012","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5935\/0004-2749.20160109","article-title":"Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis","volume":"79","author":"Gokce","year":"2016","journal-title":"Arq. Bras. Oftalmol."},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.preteyeres.2005.01.004","article-title":"Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases","volume":"24","author":"Jonas","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study","volume":"2","author":"Campochiaro","year":"2017","journal-title":"Ophthalmol. Retina"},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/jop.2014.0094","article-title":"Intravitreal triamcinolone Acetonide in the treatment of ophthalmic inflammatory diseases with macular edema: a meta-analysis study","volume":"31","author":"Claudio","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/138945011794182746","article-title":"Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration","volume":"12","author":"Becerra","year":"2011","journal-title":"Curr. Drug Targets"},{"issue":"15","key":"10.1016\/j.jconrel.2021.05.035_bb0160","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1517\/14656560903160671","article-title":"The use of intraocular corticosteroids","volume":"10","author":"Kiernan","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.jconrel.2021.05.035_bb0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00417-001-0398-y","article-title":"Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells","volume":"240","author":"Wang","year":"2002","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"3","key":"10.1016\/j.jconrel.2021.05.035_bb0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1442-9071.2001.00407.x","article-title":"Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration","volume":"29","author":"Penfold","year":"2001","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"3","key":"10.1016\/j.jconrel.2021.05.035_bb0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","article-title":"Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy","volume":"16","author":"Hussain","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2021.05.035_bb0180","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2007.12.031","article-title":"Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema","volume":"145","author":"Shimura","year":"2008","journal-title":"Am J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0190","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0b013e31816b316e","article-title":"EDWIN H RYAN, J.; Mittra, R. a., Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration","volume":"28","author":"Smith","year":"2008","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.jconrel.2021.05.035_bb0195","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0161-6420(03)00544-X","article-title":"Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization","volume":"110","author":"Spaide","year":"2003","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0200","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/IAE.0000000000000486","article-title":"Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation","volume":"35","author":"Maruko","year":"2015","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0205","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/archophthalmol.2010.69","article-title":"Inhibition of choroidal neovascularization by intravitreal ketorolac","volume":"128","author":"Kim","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2021.05.035_bb0210","doi-asserted-by":"crossref","first-page":"9898","DOI":"10.1038\/srep09898","article-title":"The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe","volume":"5","author":"Takata","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0215","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00006982-200506000-00017","article-title":"Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide","volume":"25","author":"Kato","year":"2005","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.jconrel.2021.05.035_bb0220","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1167\/iovs.08-1892","article-title":"Neuroprotective effect of intravitreal triamcinolone acetonide against photoreceptor apoptosis in a rabbit model of subretinal hemorrhage","volume":"49","author":"Bhisitkul","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2021.05.035_bb0225","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1167\/iovs.14-16250","article-title":"Systemic and Intravitreal delivery of Dendrimers to activated microglia\/macrophage in ischemia\/reperfusion mouse retina","volume":"56","author":"Kambhampati","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2021.05.035_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2010.01.052","article-title":"Triamcinolone crystal size","volume":"117","author":"Kleinman","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0235","first-page":"719","article-title":"Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation","volume":"5","author":"Sonmez","year":"2012","journal-title":"Int. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0240","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00006982-200605000-00006","article-title":"Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study","volume":"26","author":"Yu","year":"2006","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.jconrel.2021.05.035_bb0245","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ymthe.2017.01.014","article-title":"Targeted intraceptor nanoparticle for neovascular macular degeneration: preclinical dose optimization and toxicology assessment","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2021.05.035_bb0250","first-page":"1096","article-title":"Dry AMD - cellular and genetic therapies","volume":"236","author":"Johnen","year":"2019","journal-title":"Klin. Monatsbl. Augenheilkd."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0255","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/nn305958y","article-title":"Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration","volume":"7","author":"Luo","year":"2013","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.jconrel.2021.05.035_bb0260","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ymthe.2017.01.014","article-title":"Targeted Intraceptor nanoparticle for Neovascular macular degeneration: preclinical dose optimization and toxicology assessment","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"issue":"31","key":"10.1016\/j.jconrel.2021.05.035_bb0265","doi-asserted-by":"crossref","first-page":"25668","DOI":"10.1021\/acsami.7b07896","article-title":"Ex vivo rat eye model for investigating transport of next generation precision-polyester nanosystems","volume":"9","author":"Ganugula","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0270","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.tibtech.2018.01.006","article-title":"Nanotechnology-based strategies for siRNA brain delivery for disease therapy","volume":"36","author":"Zheng","year":"2018","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2021.05.035_bb0275","series-title":"Dendrimers as Drug Nanocarriers: The Future of Gene Therapy and Targeted Therapies in Cancer","author":"Franiak-Pietryga","year":"2018"},{"key":"10.1016\/j.jconrel.2021.05.035_bb0280","doi-asserted-by":"crossref","first-page":"108391","DOI":"10.1016\/j.exer.2020.108391","article-title":"Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model","volume":"203","author":"Kim","year":"2021","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154437","article-title":"Dendrimers target the ischemic lesion in rodent and primate models of nonarteritic anterior ischemic optic neuropathy","volume":"11","author":"Guo","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2021.05.035_bb0290","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1021\/nn404872e","article-title":"Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest","volume":"8","author":"Mishra","year":"2014","journal-title":"ACS Nano"},{"issue":"471","key":"10.1016\/j.jconrel.2021.05.035_bb0295","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0237","article-title":"Cognitive impairments induced by necrotizing enterocolitis can be prevented by inhibiting microglial activation in mouse brain","volume":"10","author":"Ni\u00f1o","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2021.05.035_bb0300","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.nano.2017.06.014","article-title":"Uptake of dendrimer-drug by different cell types in the hippocampus after hypoxic\u2013ischemic insult in neonatal mice: effects of injury, microglial activation and hypothermia","volume":"13","author":"Nemeth","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2021.05.035_bb0305","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.biomaterials.2016.05.044","article-title":"Nanoscale effects in dendrimer-mediated targeting of neuroinflammation","volume":"101","author":"Nance","year":"2016","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2021.05.035_bb0310","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.biomaterials.2011.10.010","article-title":"Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration","volume":"33","author":"Iezzi","year":"2012","journal-title":"Biomaterials"},{"issue":"13","key":"10.1016\/j.jconrel.2021.05.035_bb0315","first-page":"5759","article-title":"Neuroprotective bioactivity of NPD1 and Dendrimer-NPD1 in the S334-ter-5 model of retinitis Pigmentosa","volume":"55","author":"Cruz-Inigo","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2021.05.035_bb0320","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejpb.2015.02.013","article-title":"Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells","volume":"95","author":"Kambhampati","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0325","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.2353\/ajpath.2010.090989","article-title":"A rat model for choroidal neovascularization using subretinal lipid hydroperoxide injection","volume":"176","author":"Baba","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/gm315","article-title":"Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks","volume":"4","author":"Newman","year":"2012","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.jconrel.2021.05.035_bb0335","first-page":"477","article-title":"Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid","volume":"34","author":"Lutty","year":"1993","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2021.05.035_bb0340","article-title":"Preferential and increased uptake of hydroxyl-terminated PAMAM dendrimers by activated microglia in rabbit brain mixed glial culture","volume":"23","author":"Alnasser","year":"2018","journal-title":"Mol. (Basel, Switzerland)"},{"key":"10.1016\/j.jconrel.2021.05.035_bb0345","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2015.07.009","article-title":"Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury","volume":"214","author":"Nance","year":"2015","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2021.05.035_bb0350","first-page":"1217","article-title":"Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion","volume":"120","author":"Ip","year":"2002","journal-title":"Arch. Ophthalmol."},{"issue":"12","key":"10.1016\/j.jconrel.2021.05.035_bb0355","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1167\/iovs.06-0156","article-title":"A novel imaging technique for experimental choroidal neovascularization","volume":"47","author":"Campos","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2021.05.035_bb0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1189\/jlb.0902436","article-title":"The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization","volume":"74","author":"Tsutsumi","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0365","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.exer.2006.07.007","article-title":"Inhibition of TNF-\u03b1 reduces laser-induced choroidal neovascularization","volume":"83","author":"Shi","year":"2006","journal-title":"Exp. Eye Res."},{"issue":"10","key":"10.1016\/j.jconrel.2021.05.035_bb0370","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archophthalmol.2010.227","article-title":"Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration","volume":"128","author":"Jonas","year":"2010","journal-title":"Arch. Ophthalmol."},{"issue":"9","key":"10.1016\/j.jconrel.2021.05.035_bb0375","first-page":"3125","article-title":"Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells","volume":"43","author":"Penfold","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2021.05.035_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.01.013","article-title":"Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal detachment and the effect of intravitreal triamcinolone acetonide","volume":"155","author":"Kunikata","year":"2013","journal-title":"Am J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.jconrel.2021.05.035_bb0385","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1167\/iovs.09-4360","article-title":"Recombinant human VEGF165b inhibits experimental choroidal neovascularization","volume":"51","author":"Hua","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2021.05.035_bb0390","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1167\/iovs.12-11380","article-title":"The role of macrophage class a scavenger receptors in a laser-induced murine choroidal neovascularization model","volume":"54","author":"Jawad","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2021.05.035_bb0395","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/09273948.2016.1245758","article-title":"A review of the role of intravitreal corticosteroids as an adjuvant to antibiotics in infectious endophthalmitis","volume":"26","author":"Ching Wen Ho","year":"2018","journal-title":"Ocular Immunol. Inflam."},{"issue":"4","key":"10.1016\/j.jconrel.2021.05.035_bb0400","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-008-9812-z","article-title":"Intraocular sustained-release delivery systems for triamcinolone acetonide","volume":"26","author":"Mansoor","year":"2009","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.jconrel.2021.05.035_bb0405","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1021\/mp400371r","article-title":"Biodistribution of fluorescently labeled PAMAM dendrimers in neonatal rabbits: effect of neuroinflammation","volume":"10","author":"Lesniak","year":"2013","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2021.05.035_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10160","article-title":"Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration","volume":"5","author":"Liaw","year":"2020","journal-title":"Bioeng. Transl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921002601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921002601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:06:31Z","timestamp":1759161991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921002601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":82,"alternative-id":["S0168365921002601"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.035","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}